I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, TUS-PHARMA (000590.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 343 million yuan, a year-on-year decrease of 15.18%. The net loss attributable to shareholders of the listed company was 125 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 170 million yuan. The basic loss per share was 0.524 yuan.
During the reporting period, affected by market conditions and other factors, the company's total operating revenue declined compared to the same period last year. Additionally, the rise in prices of some raw and auxiliary materials led to a decrease in overall gross profit margin and profitability, while goodwill impairment and performance compensation also had a significant impact on the performance
